A PSA-guided approach for a better diagnosis of prostatic adenocarcinoma based on MALDI profiling and peptide identification

Chiara Fania, Ilaria Sogno, Michele Vasso, Enrica Torretta, Roberta Leone, Antonino Bruno, Paolo Consonni, Adriana Albini, Cecilia Gelfi

Research output: Contribution to journal › Article

10 Citations (Scopus)

Abstract

Background: Prostate cancer (PCa) is the second cause of mortality in men worldwide. The prostate-specific antigen (PSA) test is routinely adopted in diagnosis; nevertheless more reliable biomarkers are continuously under investigation by monitoring the release of molecules into the bloodstream. The serum protein profiles appear to provide cancer-specific fingerprints that help to discriminate patients (especially with low PSA level) from controls, improving the performance of existing clinical tests. Methods: Samples from healthy controls and PCa patients with low (≤. 4. ng/mL) and high PSA (>. 4. ng/mL) levels were analyzed by MALDI profiling, and by a multi fractionation approach coupled to ESI-MS for peaks identification. Results: MALDI profiling achieved to detect 10 and 14 changed peaks (p-value

Original languageEnglish
Pages (from-to)42-49
Number of pages8
JournalClinica Chimica Acta
Volume439
DOIs
Publication statusPublished - Oct 12 2014

Fingerprint

Matrix-Assisted Laser Desorption-Ionization Mass Spectrometry
Prostate-Specific Antigen
Adenocarcinoma
Peptides
Prostatic Neoplasms
Dermatoglyphics
Biomarkers
Fractionation
Blood Proteins
Molecules
Mortality
Monitoring
Neoplasms

Keywords

  • Complement C3f
  • Immunodepletion
  • MALDI profiling
  • Prostate cancer
  • Prostate-specific antigen

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Biochemistry, medical
  • Medicine(all)

Cite this

A PSA-guided approach for a better diagnosis of prostatic adenocarcinoma based on MALDI profiling and peptide identification. / Fania, Chiara; Sogno, Ilaria; Vasso, Michele; Torretta, Enrica; Leone, Roberta; Bruno, Antonino; Consonni, Paolo; Albini, Adriana; Gelfi, Cecilia.

In: Clinica Chimica Acta, Vol. 439, 12.10.2014, p. 42-49.

Research output: Contribution to journal › Article

Fania, C, Sogno, I, Vasso, M, Torretta, E, Leone, R, Bruno, A, Consonni, P, Albini, A & Gelfi, C 2014, 'A PSA-guided approach for a better diagnosis of prostatic adenocarcinoma based on MALDI profiling and peptide identification', Clinica Chimica Acta, vol. 439, pp. 42-49. https://doi.org/10.1016/j.cca.2014.10.003
Fania C, Sogno I, Vasso M, Torretta E, Leone R, Bruno A et al. A PSA-guided approach for a better diagnosis of prostatic adenocarcinoma based on MALDI profiling and peptide identification. Clinica Chimica Acta. 2014 Oct 12;439:42-49. https://doi.org/10.1016/j.cca.2014.10.003
Fania, Chiara ; Sogno, Ilaria ; Vasso, Michele ; Torretta, Enrica ; Leone, Roberta ; Bruno, Antonino ; Consonni, Paolo ; Albini, Adriana ; Gelfi, Cecilia. / A PSA-guided approach for a better diagnosis of prostatic adenocarcinoma based on MALDI profiling and peptide identification. In: Clinica Chimica Acta. 2014 ; Vol. 439. pp. 42-49.
@article{f31bcaf05d8b465a924debed90797392,
title = "A PSA-guided approach for a better diagnosis of prostatic adenocarcinoma based on MALDI profiling and peptide identification",
abstract = "Background: Prostate cancer (PCa) is the second cause of mortality in men worldwide. The prostate-specific antigen (PSA) test is routinely adopted in diagnosis; nevertheless more reliable biomarkers are continuously under investigation by monitoring the release of molecules into the bloodstream. The serum protein profiles appear to provide cancer-specific fingerprints that help to discriminate patients (especially with low PSA level) from controls, improving the performance of existing clinical tests. Methods: Samples from healthy controls and PCa patients with low (≤. 4. ng/mL) and high PSA (>. 4. ng/mL) levels were analyzed by MALDI profiling, and by a multi fractionation approach coupled to ESI-MS for peaks identification. Results: MALDI profiling achieved to detect 10 and 14 changed peaks (p-value",
keywords = "Complement C3f, Immunodepletion, MALDI profiling, Prostate cancer, Prostate-specific antigen",
author = "Chiara Fania and Ilaria Sogno and Michele Vasso and Enrica Torretta and Roberta Leone and Antonino Bruno and Paolo Consonni and Adriana Albini and Cecilia Gelfi",
year = "2014",
month = "10",
day = "12",
doi = "10.1016/j.cca.2014.10.003",
language = "English",
volume = "439",
pages = "42--49",
journal = "Clinica Chimica Acta",
issn = "0009-8981",
publisher = "Elsevier",

}

TY - JOUR

T1 - A PSA-guided approach for a better diagnosis of prostatic adenocarcinoma based on MALDI profiling and peptide identification

AU - Fania, Chiara

AU - Sogno, Ilaria

AU - Vasso, Michele

AU - Torretta, Enrica

AU - Leone, Roberta

AU - Bruno, Antonino

AU - Consonni, Paolo

AU - Albini, Adriana

AU - Gelfi, Cecilia

PY - 2014/10/12

Y1 - 2014/10/12

N2 - Background: Prostate cancer (PCa) is the second cause of mortality in men worldwide. The prostate-specific antigen (PSA) test is routinely adopted in diagnosis; nevertheless more reliable biomarkers are continuously under investigation by monitoring the release of molecules into the bloodstream. The serum protein profiles appear to provide cancer-specific fingerprints that help to discriminate patients (especially with low PSA level) from controls, improving the performance of existing clinical tests. Methods: Samples from healthy controls and PCa patients with low (≤. 4. ng/mL) and high PSA (>. 4. ng/mL) levels were analyzed by MALDI profiling, and by a multi fractionation approach coupled to ESI-MS for peaks identification. Results: MALDI profiling achieved to detect 10 and 14 changed peaks (p-value

AB - Background: Prostate cancer (PCa) is the second cause of mortality in men worldwide. The prostate-specific antigen (PSA) test is routinely adopted in diagnosis; nevertheless more reliable biomarkers are continuously under investigation by monitoring the release of molecules into the bloodstream. The serum protein profiles appear to provide cancer-specific fingerprints that help to discriminate patients (especially with low PSA level) from controls, improving the performance of existing clinical tests. Methods: Samples from healthy controls and PCa patients with low (≤. 4. ng/mL) and high PSA (>. 4. ng/mL) levels were analyzed by MALDI profiling, and by a multi fractionation approach coupled to ESI-MS for peaks identification. Results: MALDI profiling achieved to detect 10 and 14 changed peaks (p-value

KW - Complement C3f

KW - Immunodepletion

KW - MALDI profiling

KW - Prostate cancer

KW - Prostate-specific antigen

UR - http://www.scopus.com/inward/record.url?scp=84910051031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84910051031&partnerID=8YFLogxK

U2 - 10.1016/j.cca.2014.10.003

DO - 10.1016/j.cca.2014.10.003

M3 - Article

C2 - 25312866

AN - SCOPUS:84910051031

VL - 439

SP - 42

EP - 49

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

ER -

Access to Document